Barclays
ABEO icon

Barclays’s Abeona Therapeutics ABEO Stock Holding History

Barclays’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Buy
356,427
+329,179
+1,208% +$1.81M ﹤0.01% 2290
2026
Q1 		$122K Sell
27,248
-72,063
-73% -$360K ﹤0.01% 3941
2025
Q4 		$523K Buy
99,311
+37,014
+59% +$186K ﹤0.01% 3820
2025
Q3 		$329K Sell
62,297
-14,104
-18% -$89.5K ﹤0.01% 4047
2025
Q2 		$434K Sell
76,401
-8,364
-10% -$47.6K ﹤0.01% 3835
2025
Q1 		$403K Buy
84,765
+28,649
+51% +$156K ﹤0.01% 3650
2024
Q4 		$313K Buy
56,116
+1,116
+2% +$6.87K ﹤0.01% 4098
2024
Q3 		$348K Sell
55,000
-21,394
-28% -$112K ﹤0.01% 3989
2024
Q2 		$324K Buy
76,394
+20,000
+35% +$102K ﹤0.01% 3302
2024
Q1 		$409K Sell
56,394
-113,338
-67% -$718K ﹤0.01% 3713
2023
Q4 		$850K Sell
169,732
-201,544
-54% -$887K ﹤0.01% 3561
2023
Q3 		$1.56M Buy
371,276
+185,638
+100% +$702K ﹤0.01% 2039
2023
Q2 		$748K Hold
185,638
– – ﹤0.01% 2504
2023
Q1 		$523K Hold
185,638
– – ﹤0.01% 3241
2022
Q4 		$572K Buy
185,638
+181,978
+4,972% +$681K ﹤0.01% 3228
2022
Q3 		$11K Buy
+3,660
New +$15.1K ﹤0.01% 4248
2021
Q4 		– Sell
-319
Closed -$9K – 4089
2021
Q3 		$9K Sell
319
-885
-74% -$28.3K ﹤0.01% 4526
2021
Q2 		$47K Sell
1,204
-820
-41% -$33.5K ﹤0.01% 4154
2021
Q1 		$95K Sell
2,024
-1,224
-38% -$67.4K ﹤0.01% 4024
2020
Q4 		$128K Sell
3,248
-1,896
-37% -$64.6K ﹤0.01% 4012
2020
Q3 		$131K Sell
5,144
-3,040
-37% -$192K ﹤0.01% 4094
2020
Q2 		$597K Buy
8,184
+683
+9% +$47.2K ﹤0.01% 3193
2020
Q1 		$394K Buy
7,501
+1,108
+17% +$74K ﹤0.01% 3777
2019
Q4 		$522K Buy
6,393
+4,085
+177% +$288K ﹤0.01% 4268
2019
Q3 		$131K Buy
2,308
+1,275
+123% +$95.5K ﹤0.01% 5272
2019
Q2 		$123K Buy
1,033
+497
+93% +$83.3K ﹤0.01% 5523
2019
Q1 		$99K Sell
536
-1,979
-79% -$354K ﹤0.01% 5364
2018
Q4 		$450K Buy
2,515
+1,632
+185% +$356K ﹤0.01% 3906
2018
Q3 		$283K Buy
883
+738
+509% +$262K ﹤0.01% 4727
2018
Q2 		$58K Sell
145
-225
-61% -$98.3K ﹤0.01% 5564
2018
Q1 		$132K Sell
370
-492
-57% -$183K ﹤0.01% 5180
2017
Q4 		$341K Sell
862
-7,216
-89% -$2.98M ﹤0.01% 4215
2017
Q3 		$3.44M Buy
8,078
+8,036
+19,133% +$2.16M ﹤0.01% 1829
2017
Q2 		$7K Sell
42
-998
-96% -$136K ﹤0.01% 6139
2017
Q1 		$131K Buy
+1,040
New +$134K ﹤0.01% 4684
2016
Q3 		– Sell
-8
Closed – – 6577
2016
Q2 		$0 Buy
+8
New +$547 ﹤0.01% 6291
2015
Q4 		– Sell
-2
Closed – – 5941
2015
Q3 		$0 Sell
2
-6
-75% -$796 ﹤0.01% 6799
2015
Q2 		$1K Buy
+8
New +$1.2K ﹤0.01% 6896

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays's ABEO Position: Q2 2026 in Review

Barclays increased its Abeona Therapeutics (ABEO) stake by 1,208% in Q2 2026, buying an estimated $1.81M and bringing the position to 356,427 shares worth $2.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2290.

Barclays first reported a position in ABEO in Q2 2015 and has held it in 38 quarters since. The position peaked at $3.44M in Q3 2017. 127 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Barclays held 356,427 shares of Abeona Therapeutics worth $2.2M as of Q2 2026.
  • Barclays bought 329,179 Abeona Therapeutics shares in Q2 2026, an estimated $1.81M.
  • Abeona Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2290 holding.
  • Barclays first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 38 quarters since.
  • Barclays's Abeona Therapeutics position peaked at $3.44M in Q3 2017.
  • 127 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.